Joseph Baroldi sold $1.9M of IONS
EVP, Chief Business Officer at IONIS PHARMACEUTICALS INC. 32,800 shares at an average of $59.34, traded Sep 3, 2025, filed Sep 4, 2025.
Score components
- +15RoleOfficer
- +25Trade size$1.9M at market
- +20Share of holdings soldSold 94% of holdings
- +15Cluster13 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +16.5%, 3m +37.8%, 6m +26.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874015-25-000215, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 3, 2025 | MOption exercise Common Stock10b5-1 | +2,800 | $31.80 | $89k | 34,726 | Sep 4, 2025 |
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -2,800 | $62.01 | $174k | 31,926 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Common Stock10b5-1 | +15,000 | $31.80 | $477k | 46,926 | Sep 4, 2025 |
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -30,000 | $59.09 | $1.8M | 16,926 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Common Stock10b5-1 | +15,000 | $31.80 | $477k | 31,926 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -2,800 | $0.00 | $0 | 83,900 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 68,900 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 53,900 | Sep 4, 2025 |
Related signals
Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $452k 5,635 shares | -55% | |
| 7Weak | IONIS PHARMACEUTICALS INC | Spencer R Berthelsen director | $588k 8,000 shares | -5% | |
| 0Weak | IONIS PHARMACEUTICALS INC | Spencer R Berthelsen director | $605k 8,000 shares | -5% | |
| 13Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $117k 1,626 shares | -3% | |
| 36Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $419k 5,619 shares | -11% | |
| 23Weak | IONIS PHARMACEUTICALS INC | Brian Birchler EVP, Corp and Development Ops | $73k 973 shares | -1% | |
| 37Weak | IONIS PHARMACEUTICALS INC | Shannon L. Devers EVP, Chief Human Resources Ofc | $459k 6,193 shares | -27% | |
| 26Weak | IONIS PHARMACEUTICALS INC | Eugene Schneider EVP, Chf Clinical Develop Ofcr | $412k 5,812 shares | -8% | |
| 47Moderate | IONIS PHARMACEUTICALS INC | Elizabeth L Hougen EVP, Finance & CFO | $16M 225,220 shares | -73% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Kyle Jenne EVP, Chf GL Pdt Str Ofcr | $2.8M 37,277 shares | -76% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.